Clinical Trial Update: Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tirelizumab plus surgery versus surgery alone for recurrent nasopharyngeal carcinoma is ongoing with status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Tirelizumab (tirelizumab)

Snippet

Sponsor: Eye & ENT Hospital of Fudan University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN